...
首页> 外文期刊>Scientific reports. >A genomic screen for long noncoding RNA genes epigenetically silenced by aberrant DNA methylation in colorectal cancer
【24h】

A genomic screen for long noncoding RNA genes epigenetically silenced by aberrant DNA methylation in colorectal cancer

机译:对长的非编码RNA基因的基因组屏幕表观遗传学通过在结肠直肠癌中异常的DNA甲基化沉默

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Long noncoding RNAs (lncRNAs) have emerged as key components in multiple cellular processes, although their physiological and pathological functions are not fully understood. To identify cancer-related lncRNAs, we screened for those that are epigenetically silenced in colorectal cancer (CRC). Through a genome-wide analysis of histone modifications in CRC cells, we found that the transcription start sites (TSSs) of 1,027 lncRNA genes acquired trimethylation of histone H3 lysine 4 (H3K4me3) after DNA demethylation. Integrative analysis of chromatin signatures and the DNA methylome revealed that the promoter CpG islands (CGIs) of 66 lncRNA genes contained cancer-specific methylation. By validating the expression and methylation of lncRNA genes in CRC cells, we ultimately identified 20 lncRNAs, including ZNF582-AS1, as targets of epigenetic silencing in CRC. ZNF582-AS1 is frequently methylated in CRC cell lines (87.5%), primary CRCs (77.2%), colorectal adenomas (44.7%) and advanced adenomas (87.8%), suggesting that this methylation is an early event during colorectal tumorigenesis. Methylation of ZNF582-AS1 is associated with poor survival of CRC patients, and ectopic expression of ZNF582-AS1 suppressed colony formation by CRC cells. Our findings offer insight into the association between epigenetic alterations and lncRNA dysregulation in cancer and suggest that ZNF582-AS1 may be a novel tumor-suppressive lncRNA.
机译:虽然它们的生理和病理功能尚未完全理解,但是长时间的Noncoding RNA(LNCRNA)已成为多个细胞过程中的关键组分。为了鉴定与癌症相关的LNCRNA,我们筛查那些在结肠直肠癌(CRC)中表现出看起来的那些。通过对CRC细胞中的组蛋白修饰的基因组分析,我们发现在DNA去甲基化后,在1,027个LNCRNA基因的转录起始位点(TSSS)在DNA去甲基化后获得了组蛋白H3赖氨酸4(H3K4ME3)的三甲基化。染色质签约的整合分析和DNA甲基族显示,66个LNCRNA基因的启动子CpG岛(CGI)含有癌症特异性甲基化。通过验证CRC细胞中LNCRNA基因的表达和甲基化,我们最终鉴定了20个LNCRNA,包括ZNF582-AS1,作为CRC中的表观遗传沉默的靶标。 ZnF582-AS1经常在CRC细胞系中甲基化(87.5%),初级CRC(77.2%),结直肠腺瘤(44.7%)和晚期腺瘤(87.8%),表明该甲基化是结肠直肠瘤瘤期间的早期事件。 ZnF582-AS1的甲基化与CRC患者的不良存活率相关,CRC细胞的ZnF582-AS1抑制菌落形成的异位表达。我们的调查结果介绍了癌症在表观遗传学和LNCRNA失调之间的关联,并表明ZNF582-AS1可以是一种新型肿瘤抑制LNCRNA。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号